ArticlePharmaceutics2024

A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia.

Sara Galimberti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.